Form 8-K - Current report:
SEC Accession No. 0001628280-25-031819
Filing Date
2025-06-17
Accepted
2025-06-17 16:01:55
Documents
12
Period of Report
2025-06-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20250617.htm   iXBRL 8-K 39770
  Complete submission text file 0001628280-25-031819.txt   159369

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20250617.xsd EX-101.SCH 1788
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20250617_lab.xml EX-101.LAB 22543
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20250617_pre.xml EX-101.PRE 13047
14 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20250617_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 251053254
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)